Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.67 |
| ▸ | MAPT | P10636 | 2/20 | 0.67 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.56 |
| ▸ | IDO1 | P14902 | 1/20 | 0.46 |
| ▸ | APP | P05067 | 4/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | CTSD | P07339 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL232188 | 0.85 | MAPT (0.78) | ALDH1A1MAPTL3MBTL1IDO1TDP1 | |
| SCHEMBL6642732 | 0.84 | ALDH1A1 (0.76) | ALDH1A1MAPTL3MBTL1APPTDP1 | |
| SCHEMBL1562142 | 0.82 | MAPT (0.74) | ALDH1A1MAPTL3MBTL1IDO1TDP1 | |
| SCHEMBL6416019 | 0.82 | MAPT (0.74) | ALDH1A1MAPTL3MBTL1IDO1TDP1 | |
| SCHEMBL7498532 | 0.82 | ALDH1A1 (0.73) | ALDH1A1MAPTL3MBTL1APPHRH3 | |
| SCHEMBL23016009 | 0.81 | ALDH1A1 (0.64) | ALDH1A1MAPTL3MBTL1IDO1TDP1 | |
| SCHEMBL307775 | 0.81 | ALDH1A1 (0.64) | ALDH1A1MAPTL3MBTL1IDO1TDP1 | |
| SCHEMBL17711572 | 0.80 | ALDH1A1 (0.70) | ALDH1A1MAPTL3MBTL1APP | |
| SCHEMBL4073240 | 0.80 | — | — | |
| SCHEMBL4970157 | 0.80 | ALDH1A1 (0.89) | ALDH1A1MAPTL3MBTL1TDP1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2528595-B1 | COMPOUNDS FOR USE IN THE TREATMENT OF DISEASES | INOXIA LIFESCIENCES GMBH (AT) | 2015-08-05 | — | — | EP | claimed |
| JP-63227552-A | — | — | None | — | — | JP | disclosed |
| WO-2025107026-A1 | TSPO LIGANDS | THE UNIVERSITY OF SYDNEY (AU) | 2025-05-30 | — | — | WO | disclosed |
| EP-2411362-B1 | Tricyclic indole derivatives as PBR ligands | GE HEALTHCARE LTD (GB) | 2017-05-31 | — | — | EP | disclosed |
| US-9314541-B2 | In vivo imaging method for cancer | GE HEALTHCARE LIMITED (GB) | 2016-04-19 | — | — | US | disclosed |
| US-9220795-B2 | Indole derivatives | GE HEALTHCARE LIMITED (GB) | 2015-12-29 | — | — | US | disclosed |
| US-9168317-B2 | In vivo imaging method of mood disorders | GE HEALTHCARE LIMITED (GB) | 2015-10-27 | — | — | US | disclosed |
| US-20140364615-A1 | INDOLE DERIVATIVES | GE HEALTHCARE LIMITED (GB) | 2014-12-11 | — | — | US | disclosed |
| US-8790619-B2 | Indole derivatives | GE HEALTHCARE LIMITED (GB) | 2014-07-29 | — | — | US | disclosed |
| EP-2621544-A1 | IN VIVO IMAGING METHOD FOR CANCER | GE Healthcare UK Limited (GB) | 2013-08-07 | — | — | EP | disclosed |
| CN-103179991-A | In vivo imaging method for cancer | GE HEALTHCARE LTD | 2013-06-26 | — | — | CN | disclosed |
| CN-102448933-A | Indole Derivatives as PBR Ligands | GE HEALTHCARE LTD | 2012-05-09 | — | — | CN | disclosed |
| WO-2012041953-A1 | IN VIVO IMAGING METHOD FOR CANCER | GE HEALTHCARE LIMITED (GB) | 2012-04-05 | — | — | WO | disclosed |
| WO-2012038532-A1 | IN VIVO IMAGING METHOD OF MOOD DISORDERS | GE HEALTHCARE LIMITED (GB) | 2012-03-29 | — | — | WO | disclosed |
| EP-2411362-A2 | INDOLE DERIVATIVES | GE Healthcare UK Limited (GB) | 2012-02-01 | — | — | EP | disclosed |
| US-20120020884-A1 | INDOLE DERIVATIVES | GE HEALTHCARE LIMITED (GB) | 2012-01-26 | — | — | US | disclosed |
| WO-2010109007-A2 | INDOLE DERIVATIVES | GE HEALTHCARE LIMITED (GB) | 2010-09-30 | — | — | WO | disclosed |
| EP-1450796-B1 | BENZOTHIAZOLE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2008-04-09 | — | — | EP | disclosed |
| JP-S63227552-A | 2-FLUOROETHYL DERIVATIVE, PRODUCTION THEREOF PEST EXTERMINATING AGENT CONTAINING SAID DERIVATIVE AS ACTIVE INGREDIENT | SHIONOGI & CO LTD | 1988-09-21 | — | — | JP | disclosed |
| US-3997519-A | Method of producing quaternary pyridinium compounds | GAF CORPORATION (US) | 1976-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120020884-A1 | INDOLE DERIVATIVES | IDO1, IDO2, INMT | ALDH1A1 2535/4885MAPT 2852/4885L3MBTL1 4359/4885 |
| US-20140364615-A1 | INDOLE DERIVATIVES | IDO1, IDO2, INMT | ALDH1A1 2535/4885MAPT 2852/4885L3MBTL1 4359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.